Newsletter mensile Aiom
Anno V – Numero 52, Febbraio 2023
Comitato scientifico editoriale: Vanna Chiarion Sileni, Paola Queirolo
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini
 
Notizie dalla ricerca


Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory approval. Little prospective data exist to guide the choice of either initial therapy or treatment sequence in this population. This study was conducted to determine which initial treatment or treatment sequence … Continua a leggere




Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy

To evaluate the efficacy and safety of cobimetinib plus atezolizumab in the treatment of patients with advanced BRAFV600 wild-type melanoma who had progressed on prior anti‒programmed death-1 (PD-1) therapy. This phase 1b, open-label, international multicentre study enrolled 3 cohorts. Herein, we report on patients in cohorts A and B who had progressed on prior anti‒PD-1 therapy. … Continua a leggere

 



Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684

Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma. A randomized controlled study of IFN alpha-2b (Schering-Plough, Kenilworth, NJ) administered at maximum-tolerated doses of 20 MU/m2/d intravenously (i.v.) for 1 month and 10 MU/m2 three times per week subcutaneously (SC) … Continua a leggere

 



Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials

Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in macroscopic stage III melanoma patients. These response rates translated to high short-term survival rates. However, data on long-term survival and disease recurrence are lacking. In OpACIN, 20 macroscopic stage III melanoma patients were randomized to ipilimumab 3 mg/kg plus nivolumab 1 mg/kg q3w four cycles adjuvant or split two cycles neoadjuvant and two adjuvant. …  Continua a leggere

 



Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases


Few studies have investigated the health-related quality of life (HRQOL) in patients with melanoma in-transit metastases (ITM). The aim was to investigate the association between tumor burden and HRQOL, including disparities pertaining to sex and age, in treatment-naïve patients with ITM. Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire was used to assess HRQOL Pairwise comparisons … Continua a leggere



 

Appuntamenti Aiom

Avviso a tutti i Soci

A causa del protrarsi dell’emergenza coronavirus e delle relative disposizioni, si suggerisce di verificare la conferma dei singoli eventi direttamente con gli organizzatori

Nuove prospettive nel trattamento delle neoplasie cerebrali
I mercoledì dell’oncologia
Webinar, 8 febbraio 2023 dalle 17.00 alle 18.15

News in GI Oncology 2023
Padova, 10 – 11 febbraio 2023

Nuove prospettive nella terapia del carcinoma uroteliale localmente avanzato e metastatico
I mercoledì dell’oncologia
Webinar, 22 febbraio 2023 dalle 17.00 alle 18.15

Focus sul management dei possibili eventi avversi delle nuove terapie: l’importanza della multidisciplinarietà
I mercoledì dell’oncologia
Webinar (ECM), 8 marzo 2023 dalle 17.00 alle 18.15

News in GU Oncology 2023
Bari, 10 – 11 marzo 2023

Il trattamento del melanoma cutaneo: gestione multidisciplinare
Matera, 11 marzo 2023

ASCO-AIOM International Clinical Research Course
Roma, 31 marzo – 1° aprile 2023
Questi e altri appuntamenti si possono consultare sul sito AIOM: www.aiom.it


© 2023 Editore:
Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 388 8896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867

Per contattare la redazione e commentare le notizie clicca qui
Per consultare i numeri arretrati della newsletter clicca qui

Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy


“Si ringrazia Pierre Fabre Pharma s.r.l. per il supporto incondizionato”